## Yakult

# Supplementary Materials for Financial Statements For the second quarter Ended September 30, 2017 (April 1, 2017 to September 30, 2017) 

November 10, 2017

Yakult Honsha Co., Ltd.<br>Public Relations Department Investor Relations Department<br>URL http://www.yakult.co.jp/company/ir/

## Contents

## Consolidated

1. Major Increases (Decreases) in Consolidated Balance Sheet -•• 1 ..... Page
2. Major Increases (Decreases) in Consolidated Statement of Income ..... 2
3. Performance Overview ... 3 ..... 4
4. Segment Information ..... 5 ..... 10
5. Overview of Overseas Companies ... 11 ..... 12
Non-Consolidated
6. Major Increases (Decreases) in Non-consolidated Balance Sheet .....  13
7. Major Increases (Decreases) in Non-consolidated Statement of .....  14 Income
8. Performance Overview ..... 15
9. Breakdown of Sales .....  16 ..... 17
10. Breakdown of Selling, General and Administrative Expenses ..... -•• 18
11. Breakdown of retirement benefit expneses .....  18
12. Head Office Employees .....  18
13. Yakult Sales Company .....  18
14. Sales Personnel by Department ..... 18
15. Average figure of Yakult Lady ..... 18
Reference
16. Expansion of Indication and New Drug Development Pipeline ..... 19
17. Situation of Yakult Group ( Production Facilities ) ..... 20
18. Overseas dairy products sales amount (Preliminary figure) .....  21
About a numeric display of this material
1.Unit of money : Less than one million yen is rounded down.
2.Quantity results: Less than 1000 is rounded off.3. Year on year percentage: The second place is rounded off after the decimal point.

## Consolidated

1. Major Increases (Decreases) in Consolidated Balance Sheet
(Millions of yen)

|  | $\begin{gathered} \text { As of Mar. } 31 \\ 2017 \end{gathered}$ | $\begin{gathered} \text { As of Sep. } 30 \\ 2017 \end{gathered}$ | Increase (Decrease) | Primary reason for change |
| :---: | :---: | :---: | :---: | :---: |
| Total Assets | 585,741 | 612,671 | 26,930 |  |
| Current assets <br> Cash and deposits <br> Notes and accounts receivable Inventories <br> Others | $\begin{array}{r} 132,030 \\ 54,437 \\ 28,526 \\ 13,802 \end{array}$ | $\begin{array}{r} 140,685 \\ 61,206 \\ 29,996 \\ 14,849 \end{array}$ | $\begin{aligned} & 8,655 \\ & 6,769 \\ & 1,470 \\ & 1,047 \end{aligned}$ |  |
| Fixed assets <br> Tangible fixed assets <br> Buildings and structures <br> Others | $\begin{array}{r} 89,911 \\ 108,387 \end{array}$ | $\begin{array}{r} 87,733 \\ 107,152 \end{array}$ | $\begin{aligned} & (2,177) \\ & (1,235) \end{aligned}$ |  |
| Intangible fixed assets | 5,464 | 5,573 | 108 |  |
| Investments and other assets <br> Investment securities <br> Others | $\begin{array}{r} 143,822 \\ 9,359 \end{array}$ | $\begin{array}{r} 155,941 \\ 9,533 \end{array}$ | $\begin{array}{r} 12,118 \\ 173 \\ \hline \end{array}$ | Increase in parent company |
| Total Liabilities | 208,860 | 211,913 | 3,052 |  |
| Current liabilities <br> Notes and accounts payable <br> Short-term borrowings Others | $\begin{aligned} & 24,618 \\ & 46,670 \\ & 42,863 \end{aligned}$ | $\begin{aligned} & 29,308 \\ & 46,493 \\ & 41,954 \end{aligned}$ | $\begin{gathered} 4,690 \\ (176) \\ (909) \end{gathered}$ |  |
| Fixed liabilities <br> Long-term borrowings <br> Retirement benefit obligation Others | $\begin{array}{r} 57,491 \\ 7,471 \\ 29,744 \end{array}$ | $\begin{array}{r} 54,646 \\ 6,938 \\ 32,570 \end{array}$ | $\begin{array}{r} (2,844) \\ (532) \\ 2,826 \end{array}$ |  |
| Total Net Assets | 376,880 | 400,758 | 23,877 |  |
| Shareholder's Equity <br> Accumulated other comprehensive income <br> Non-controlling interests | $\begin{gathered} 346,354 \\ (2,851) \\ 33,378 \end{gathered}$ | $\begin{array}{r} 361,530 \\ 4,083 \\ 35,144 \end{array}$ | $\begin{array}{r} 15,176 \\ 6,934 \\ 1,766 \end{array}$ |  |

2. Major Increases (Decreases) in Consolidated Statement of Income
(Millions of yen)

\begin{tabular}{|c|c|c|c|c|c|c|}
\hline \& \multirow[t]{2}{*}{\begin{tabular}{l}
2Q of FY 2017 \\
(2016.4~9)
\end{tabular}} \& \multirow[t]{2}{*}{\[
\begin{gathered}
2 \mathrm{Q} \text { of FY } 2018 \\
(2017.4 \sim 9)
\end{gathered}
\]} \& \multicolumn{2}{|l|}{Increase (Decrease)} \& \multirow[b]{2}{*}{Primary reason for change} \& \multirow[t]{2}{*}{Original Forecasts※ (2017.4~9)} \\
\hline \& \& \& Amount \& \% \& \& \\
\hline Net sales \& 188,946 \& 197,728 \& 8,782 \& 4.6 \& FX impact ( 1,105 ) \& 199,000 \\
\hline \begin{tabular}{l}
(Sales by business segments) \\
Food and beverages (Japan) \\
Food and beverages(Overseas) \\
Pharmaceuticals \\
Others \\
Adjustment
\end{tabular} \& \[
\begin{array}{r}
102,237 \\
71,650 \\
14,453 \\
10,125 \\
(9,521)
\end{array}
\] \& \[
\begin{array}{r}
106,361 \\
79,169 \\
13,246 \\
10,633 \\
(11,682)
\end{array}
\] \& 4,124
7,518
\((1,207)\)
507
\((2,161)\) \& \& \& \\
\hline Cost of sales \& 82,411 \& 83,965 \& 1,554 \& 1.9 \& \& \\
\hline \begin{tabular}{l}
Gross profit \\
Gross profit margin (\%)
\end{tabular} \& \[
\begin{array}{r}
\hline 106,535 \\
56.4
\end{array}
\] \& \[
\begin{array}{r}
\hline 113,763 \\
57.5
\end{array}
\] \& \[
\begin{array}{r}
7,228 \\
1.1
\end{array}
\] \& 6.8 \& \& \\
\hline \begin{tabular}{l}
Selling, general and administrative expenses \\
Selling expenses \\
General and administrative expenses
\end{tabular} \& \[
\begin{aligned}
\& 87,788 \\
\& 41,103 \\
\& 46,685
\end{aligned}
\] \& \[
\begin{aligned}
\& 90,957 \\
\& 43,101 \\
\& 47,856
\end{aligned}
\] \& \[
\begin{aligned}
\& 3,168 \\
\& 1,997 \\
\& 1,171
\end{aligned}
\] \& 3.6 \& \& \\
\hline \begin{tabular}{l}
Operating income \\
Operating income margin (\%)
\end{tabular} \& \[
\begin{array}{r}
18,746 \\
9.9
\end{array}
\] \& \[
\begin{array}{r}
\hline 22,806 \\
11.5
\end{array}
\] \& \[
\begin{array}{r}
4,059 \\
1.6
\end{array}
\] \& 21.7 \& FX impact (593) \& 21,500 \\
\hline \begin{tabular}{l}
(Operating income by business segments) \\
Food and beverages (Japan) \\
Food and beverages(Overseas) \\
Pharmaceuticals \\
Others \\
Adjustment \\
\{include corporate expenses\}
\end{tabular} \& \begin{tabular}{r}
6,903 \\
18,232 \\
1,301 \\
521 \\
\\
\hline\((8,211)\) \\
\(\left\{\begin{array}{l}(6,414)\end{array}\right\}\) \\
\hline
\end{tabular} \&  \& 2,993
1,532
380
79

$\left\{\begin{array}{c}(926) \\ \{ \end{array}(238)\right\}$ \& \& \& <br>

\hline | Non-operating incomes |
| :--- |
| Interests income |
| Dividends income |
| Investment gains on the equity method |
| Others |
| Non-operating expenses |
| Interest expenses |
| Others | \& \[

$$
\begin{array}{r}
\hline 5,552 \\
1,375 \\
944 \\
1,984 \\
1,247 \\
538 \\
366 \\
172
\end{array}
$$

\] \& \[

$$
\begin{array}{r}
\hline 6,301 \\
1,864 \\
1,073 \\
2,418 \\
945 \\
2,247 \\
315 \\
1,931
\end{array}
$$

\] \& \[

$$
\begin{gathered}
\hline 749 \\
489 \\
129 \\
433 \\
(302) \\
1,708 \\
(50) \\
1,759
\end{gathered}
$$
\] \& 13.5

$$
317.1
$$ \& Mainly foreign exchange loss \& <br>

\hline | Ordinary income |
| :--- |
| Ratio of ordinary income to net sales (\%) | \& \[

$$
\begin{array}{r}
23,760 \\
12.6
\end{array}
$$

\] \& \[

$$
\begin{array}{r}
26,860 \\
13.6
\end{array}
$$

\] \& \[

$$
\begin{array}{r}
\hline 3,100 \\
1.0
\end{array}
$$
\] \& 13.0 \& FX impact (486) \& 25,500 <br>

\hline Extraordinary gain Extraordinary loss \& $$
\begin{aligned}
& \hline 241 \\
& 387
\end{aligned}
$$ \& \[

$$
\begin{aligned}
& 72 \\
& 99
\end{aligned}
$$

\] \& \[

$$
\begin{aligned}
& (168) \\
& (288)
\end{aligned}
$$

\] \& \[

$$
\begin{aligned}
& \hline(69.9) \\
& (74.4)
\end{aligned}
$$
\] \& \& <br>

\hline Income before income taxes and minority interests \& 23,613 \& 26,833 \& 3,220 \& 13.6 \& \& <br>
\hline Income taxes \& 6,096 \& 6,856 \& 759 \& \& \& <br>
\hline Profit \& 17,516 \& 19,977 \& 2,460 \& 14.0 \& \& <br>
\hline Profit attributable to non controlling interests \& 2,551 \& 2,099 \& (452) \& \& \& <br>

\hline | Profit attributable to owners of parent |
| :--- |
| Ratio of net income to net sales (\%) | \& \[

$$
\begin{array}{r}
\hline \mathbf{1 4 , 9 6 5} \\
7.9
\end{array}
$$

\] \& \[

$$
\begin{array}{r}
\mathbf{1 7 , 8 7 8} \\
9.0
\end{array}
$$

\] \& \[

$$
\begin{array}{r}
2,912 \\
1.1
\end{array}
$$
\] \& 19.5 \& FX impact (369) \& 15,500 <br>

\hline
\end{tabular}

※ Forecast for 2nd quarter of FY2018 announced on May 12, 2017

## 3. Performance Overview

(1) Breakdown of Statement of Income
(Millions of yen. \%)

|  | Fiscal year ended March 31, 2017 |  |  | Fiscal year ending March 31, 2018 |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | Result of <br> 2nd quarter | Year on <br> year | Annual <br> results | Year on <br> year | Result of <br> 2nd quarter | Year on <br> year | Annual <br> forecasts <br> $\ldots$ | Year on <br> year |
| Net sales | 188,946 | 97.2 | 378,307 | 96.9 | 197,728 | 104.6 | 402,500 | 106.4 |
| Operating income | 18,746 | 83.6 | 37,281 | 93.1 | 22,806 | 121.7 | 41,500 | 111.3 |
| Ordinary income | 23,760 | 84.0 | 49,370 | 97.5 | 26,860 | 113.0 | 51,000 | 103.3 |
| Profit attributable <br> to owners of parent | 14,965 | 88.1 | 30,154 | 104.5 | 17,878 | 119.5 | 31,500 | 104.5 |

※ The forecasts changed from the original announced on May 12, 2017
(2) Ratios of Consolidated to Non-consolidated Results
(Times)

|  | Fiscal year ended March 31, 2017 |  | Fiscal year ending March 31, 2018 |  |
| :---: | :---: | :---: | :---: | :---: |
|  | Result of 2nd quarter | Annual results | Result of 2nd quarter | Annual forecasts |
| Net sales | 2.16 | 2.18 | 2.19 | 2.30 |
| Operating income | - | 47.63 | 8.55 | 20.75 |
| Ordinary income | 8.48 | 3.90 | 4.05 | 3.78 |
| Profit attributable <br> to owners of parent | 6.29 | 2.99 | 3.12 | 2.86 |

## (3) Breakdown of Gains on Equity Method

(Millions of yen. \%)

|  | Fiscal year ended March 31, 2017 |  |  |  | Fiscal year ending March 31, 2018 |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | Result of <br> 2nd quarter | Year on <br> year | Annual <br> results | Year on <br> year | Result of <br> 2nd quarter | Year on <br> year | Annual <br> forecasts | Year on <br> year |
| Investment gains on <br> the equity method | 1,984 | 94.8 | 4,442 | 134.1 | 2,418 | 121.8 | 4,300 | 96.8 |

(4) Major Items in selling, general and administrative expenses
(Millions of yen. \%)

|  | Fiscal year ended March 31, 2017 |  |  | Fiscal year ending March 31, 2018 |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | :---: |
|  | Result of <br> 2nd quarter | Year on <br> year | Annual <br> results | Year on <br> year | Result of <br> nd quarter | Year on <br> year | Annual <br> forecasts | Year on <br> year |
| Advertising expenses | 8,409 | 123.5 | 17,279 | 120.8 | 8,821 | 104.9 | - | - |
| Sales promotion <br> expenses | 4,085 | 95.3 | 9,086 | 86.5 | 4,371 | 107.0 | - | - |
| Freight | 6,087 | 100.0 | 12,050 | 98.7 | 6,408 | 105.3 | - | - |
| Employee's salaries | 18,418 | 96.1 | 37,117 | 97.9 | 19,575 | 106.3 | - | - |
| Depreciation | 2,296 | 86.2 | 4,495 | 85.8 | 2,174 | 94.7 | - | - |
| Research and <br> Development cost | 5,226 | 85.0 | 10,511 | 83.2 | 4,791 | 91.7 | - | - |

(5) Capital investments, Depreciation and amortization, Research and development costs
(Millions of yen. \%)

|  | Fiscal year ended March 31, 2017 |  |  | Fiscal year ending March 31, 2018 |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | Result of <br> 2nd quarter | Year on <br> year | Annual <br> results | Year on <br> year | Result of <br> 2nd quarter | Year on <br> year | Annual <br> forecasts | Year on <br> year |
| Capital investments | 12,467 | 82.0 | 23,365 | 85.3 | 7,743 | 62.1 | 32,000 | 137.0 |
| Depreciation and <br> amortization | 11,294 | 95.5 | 22,660 | 93.0 | 10,528 | 93.2 | 22,000 | 97.1 |
| Research and <br> development costs | 5,246 | 85.1 | 10,549 | 83.2 | 4,810 | 91.7 | 11,130 | 105.5 |

## Breakdown of investment

|  | Fiscal year ended March 31, 2017 |  | Forecast of full fiscal year ending March 31, 2018 |  |
| :---: | :---: | :---: | :---: | :---: |
| Capital investments | Investment in Parent company Investment in Plants(subsidiaries) Investment in Overseas subsidiaries | 11.1 billion yen <br> 0.6 billion yen <br> 9.5 billion yen | Investment in Parent company Investment in Plants(subsidiaries) Investment in Overseas subsidiaries | 13.0 billion yen <br> 1.5 billion yen <br> 16.9 billion yen |
| Research and <br> Development costs | Food and beverages <br> Pharmaceuticals <br> Others | 6.3 billion yen <br> 3.4 billion yen <br> 0.6 billion yen | Food and beverages <br> Pharmaceuticals <br> Others | 6.8 billion yen <br> 3.6 billion yen <br> 0.6 billion yen |

〈Reference〉 Consolidated Statements of Cash Flows Overview
(Millions of yen)

|  | Previous period <br> $(2016.4 \sim 2016.9)$ | Current period <br> $(2017.4 \sim 2017.9)$ | Increase (Decrease) <br> Amount |
| :---: | :---: | :---: | :---: |
| Cash flows <br> from operating activities | 24,848 | 26,339 | 1,491 |
| Cash flows <br> from investing activities | $(30,588)$ | $(14,641)$ | 15,946 |
| Cash flows <br> from financing activities | 2,609 | $(8,010)$ | $110,620)$ |
| Foreign currency translation <br> adjustments on cash and cash <br> equivalents | $(9,908)$ | 1,653 | 18,378 |
| Net increase (decrease) in cash <br> and cash equivalents | $(13,038)$ | 5,340 | $(6,668)$ |
| Beginning balance of cash <br> and cash equivalents | 101,799 | 100,471 | 11,710 |
| Ending balance of cash <br> and cash equivalents | 88,760 |  | 130 |

## 4. Segment Information

(1) Result of 2nd quarter
(1) Results of 2nd quarter ended September 30, 2016 (April 1, 2016 ~ September 30, 2016)

| (Millions of yen) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Food and beverages |  |  |  |  |
|  | Japan | Overseas Total | The Americas | Asia and Oceania | Europe |
| Net sales | 102,237 | 71,650 | 23,415 | 44,055 | 4,180 |
| Percentage of net sales <br> (\%) | 54.1 | 37.9 | 12.4 | 23.3 | 2.2 |
| Year on year (\%) | 101.0 | 91.8 | 84.6 | 95.7 | 96.6 |
| Operating expenses | 95,334 | 53,418 | 17,211 | 32,506 | 3,700 |
| Year on year (\%) | 100.2 | 93.0 | 83.5 | 98.6 | 95.6 |
| Operating income (loss) | 6,903 | 18,232 | 6,203 | 11,548 | 479 |
| Year on year (\%) | 114.5 | 88.5 | 87.6 | 88.3 | 104.7 |
| Operating income margin (\%) | 6.8 | 25.4 | 26.5 | 26.2 | 11.5 |


|  | Pharmaceuticals | Others | Total | Adjustment | Consolidated |
| :---: | ---: | ---: | ---: | ---: | ---: |
| Net sales | 14,453 | 10,125 | 198,467 | $(9,521)$ | 188,946 |
| Percentage of net sales <br> (\%) | 7.6 | 5.4 | 105.0 | $(5.0)$ | 100.0 |
| Year on year (\%) | 80.8 | 108.1 | 96.1 | 77.9 | 97.2 |
| Operating expenses | 13,151 | 9,604 | 171,509 | $(1,309)$ | 170,199 |
| Year on year (\%) | 95.0 | 106.6 | 97.7 | 36.4 | 99.0 |
| Operating income <br> (loss) | 1,301 | 521 | 26,958 | $\ldots$ | $(8,211)$ |

※ The details of "Adjustment"are as follows.

- Administrative expenses in parent company : 6,414 million yen
- Elimination of royalty income : 1,796 million yen

Results of 2nd quarter ended September 30, 2017 (April 1, 2017 ~ September 30, 2017)

|  | Food and beverages |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: |
|  | Japan |  | Overseas Total | The Americas | Asia and Oceania |
|  | 106,361 | 79,169 | 25,170 | 49,917 | Europe |
| Percentage of net sales <br> (\%) | 53.8 | 40.0 | 12.7 | 25.2 | 4,080 |
| Year on year (\%) | 104.0 | 110.5 | 107.5 | 113.3 | 2.1 |
| Operating expenses | 96,464 | 59,404 | 19,034 | 36,680 | 97.6 |
| Year on year (\%) | 101.2 | 111.2 | 110.6 | 112.8 | 3,689 |
| Operating income <br> (loss) | 9,896 | 19,764 | 6,136 | 13,237 | 99.7 |
| Year on year (\%) | 143.4 | 108.4 | 98.9 | 114.6 | 390 |
| Operating income <br> margin (\%) | 9.3 | 25.0 | 24.4 | 26.5 | 81.4 |


|  | Pharmaceuticals | Others | Total | Adjustment | Consolidated |
| :---: | ---: | ---: | ---: | ---: | ---: |
| Net sales | 13,246 | 10,633 | 209,411 | $(11,682)$ | 197,728 |
| Percentage of net sales <br> (\%) | 6.7 | 5.4 | 105.9 | $(5.9)$ | 100.0 |
| Year on year (\%) | 91.6 | 105.0 | 105.5 | 122.7 | 104.6 |
| Operating expenses | 11,564 | 10,033 | 177,466 | $(2,544)$ | 174,922 |
| Year on year (\%) | 87.9 | 104.5 | 103.5 | 194.3 | 102.8 |
| Operating income <br> (loss) | 1,682 | 600 | 31,944 | ※ | $(9,138)$ |

※ The details of "Adjustment"are as follows.

- Administrative expenses in parent company : 6,653 million yen
- Elimination of royalty income : 2,484 million yen


## 〈Reference〉

Result of 2nd quarter ended September 30, 2017
(on the basis of average exchange rate between Jan. 2016 and Jun. 2016)
(3) Results of 2nd quarter ended September 30, 2017 (April 1, 2017 ~ September 30, 2017)

| (Millions of yen) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Food and beverages |  |  |  |  |
|  | Japan | Overseas Total | The Americas | Asia and Oceania | Europe |
| Net sales | 106,361 | 80,274 | 24,952 | 51,036 | 4,285 |
| Percentage of net sales <br> (\%) | 53.5 | 40.4 | 12.5 | 25.7 | 2.2 |
| Year on year (\%) | 104.0 | 112.0 | 106.6 | 115.8 | 102.5 |
| Operating expenses | 96,464 | 59,916 | 18,588 | 37,518 | 3,809 |
| Year on year (\%) | 101.2 | 112.2 | 108.0 | 115.4 | 103.0 |
| Operating income (loss) | 9,896 | 20,358 | 6,364 | 13,518 | 475 |
| Year on year (\%) | 143.4 | 111.7 | 102.6 | 117.1 | 99.2 |
| $\begin{gathered} \text { Operating income } \\ \text { margin (\%) } \end{gathered}$ | 9.3 | 25.4 | 25.5 | 26.5 | 11.1 |


|  | Pharmaceuticals | Others | Total | Adjustment | Consolidated |
| :---: | ---: | ---: | ---: | ---: | ---: |
| Net sales | 13,246 | 10,633 | 210,516 | $(11,682)$ | 198,834 |
| Percentage of net sales <br> (\%) | 6.7 | 5.3 | 105.9 | $(5.9)$ | 100.0 |
| Year on year (\%) | 91.6 | 105.0 | 106.1 | 122.7 | 105.2 |
| Operating expenses | 11,564 | 10,033 | 177,978 | $(2,544)$ | 175,434 |
| Year on year (\%) | 87.9 | 104.5 | 103.8 | 194.3 | 103.1 |
| Operating income <br> (loss) | 1,682 | 600 | 32,537 | $\ldots$ | $(9,138)$ |
| Year on year (\%) | 129.2 | 115.2 | 120.7 | 111.3 | 23,399 |
| Operating income <br> margin (\%) | 12.7 | 5.6 | -- | -- | 124.8 |

※ The details of "Adjustment"are as follows.

- Administrative expenses in parent company : 6,653 million yen
- Elimination of royalty income : 2,484 million yen
(2) Annual financial forecast
(1) Result of fiscal year ended March 31, 2017 (April 1, 2016 ~ March 31, 2017)
(Millions of yen)

|  | Food and beverages |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  | Japan | Overseas Total | The Americas | Asia and Oceania | Europe |
| Net sales | 204,130 | 146,416 | 45,252 | 93,364 | 7,800 |
| Percentage of net sales (\%) | 54.0 | 38.7 | 11.9 | 24.7 | 2.1 |
| Year on year (\%) | 102.6 | 92.4 | 85.8 | 96.1 | 90.5 |
| Operating expenses | 190,317 | 110,293 | 34,928 | 68,056 | 7,308 |
| Year on year (\%) | 100.5 | 93.4 | 87.4 | 97.0 | 91.3 |
| Operating income (loss) | 13,813 | 36,123 | 10,323 | 25,307 | 491 |
| Year on year (\%) | 144.9 | 89.5 | 80.8 | 93.8 | 79.5 |
| Operating income margin (\%) | 6.8 | 24.7 | 22.8 | 27.1 | 6.3 |


|  | Pharmaceuticals | Others | Total | Adjustment | Consolidated |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Net sales | 27,836 | 19,951 | 398,336 | $(20,028)$ | 378,307 |
| Percentage of net sales (\%) | 7.3 | 5.3 | 105.3 | (5.3) | 100.0 |
| Year on year (\%) | 80.0 | 98.2 | 96.6 | 90.4 | 96.9 |
| Operating expenses | 24,946 | 19,047 | 344,604 | $(3,578)$ | 341,026 |
| Year on year (\%) | 84.7 | 100.7 | 96.8 | 64.7 | 97.3 |
| Operating income (loss) | 2,890 | 904 | 53,731 | ※ (16,449) | 37,281 |
| Year on year (\%) | 53.9 | 64.3 | 94.8 | 99.0 | 93.1 |
| Operating income margin (\%) | 10.4 | 4.5 | -- | --- | 9.9 |

※ The details of "Adjustment"are as follows.

- Administrative expenses in parent company : 12,610 million yen
- Elimination of royalty income : 3,839 million yen

Annual forecast for the fiscal year ending March 31, 2018 (April 1, 2017 ~ March 31, 2018)
(Millions of yen)

|  | Food and beverages |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: |
|  | Japan |  | Overseas Total |  | The Americas |
|  | Asia and Oceania | Europe |  |  |  |
| Percentage of net sales <br> (\%) | 210,000 | 168,000 | 50,200 | 110,000 | 7,800 |
| Year on year (\%) | 52.2 | 41.7 | 12.5 | 27.3 | 1.9 |
| Operating expenses | 102.9 | 114.7 | 110.9 | 117.8 | 100.0 |
| Year on year (\%) | 193,900 | 127,700 | 39,600 | 80,400 | 7,700 |
| Operating income <br> (loss) | 16,100 | 115.8 | 113.4 | 118.1 | 105.4 |
| Year on year (\%) | 116.6 | 10,300 | 10,600 | 29,600 | 100 |
| Operating income <br> margin (\%) | 7.7 | 24.0 | 102.7 | 117.0 | 20.3 |


|  | Pharmaceuticals | Others | Total | Adjustment | Consolidated |
| :---: | ---: | ---: | ---: | ---: | ---: |
| Net sales | 25,000 | 21,400 | 424,400 | $(21,900)$ | 402,500 |
| Percentage of net sales <br> (\%) | 6.2 | 5.3 | 105.4 | $(5.4)$ | 100.0 |
| Year on year (\%) | 89.8 | 107.3 | 106.5 | 109.3 | 106.4 |
| Operating expenses | 23,300 | 20,500 | 365,400 | $(4,400)$ | 361,000 |
| Year on year (\%) | 93.4 | 107.6 | 106.0 | 122.9 | 105.9 |
| Operating income <br> (loss) | 1,700 | 900 | 59,000 | $\ldots$ | $(17,500)$ |

※ The details of "Adjustment"are as follows.

- Administrative expenses in parent company : 12,900 million yen
- Elimination of royalty income : 4,600 million yen


## 〈Reference〉

Annual forecast for the fiscal year ending March 31, 2018
(on the basis of average exchange rate between Jan. 2016 and Dec. 2016)
(3) Annual forecast for the fiscal year ending March 31, 2018 (April 1, 2017 ~ March 31, 2018)
(Millions of yen)

|  | Food and beverages |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: |
|  | Japan |  | Overseas Total |  | The Americas |
|  | Asia and Oceania | Europe |  |  |  |
| Percentage of net sales <br> (\%) | 210,000 | 164,300 | 47,800 | 108,800 | 7,700 |
| Year on year (\%) | 52.6 | 41.2 | 12.0 | 27.3 | 1.9 |
| Operating expenses | 102.9 | 112.2 | 105.6 | 116.5 | 98.7 |
| Year on year (\%) | 193,900 | 124,500 | 37,500 | 79,500 | 7,500 |
| Operating income <br> (loss) | 16,100 | 112.9 | 107.4 | 116.8 | 102.6 |
| Year on year (\%) | 116.6 | 110.2 | 10,300 | 29,300 | 200 |
| Operating income <br> margin (\%) | 7.7 | 24.2 | 99.8 | 115.8 | 40.7 |


|  | Pharmaceuticals | Others | Total | Adjustment | Consolidated |
| :---: | ---: | ---: | ---: | ---: | ---: |
| Net sales | 25,000 | 21,400 | 420,700 | $(21,900)$ | 398,800 |
| Percentage of net sales <br> (\%) | 6.3 | 5.4 | 105.5 | $(5.5)$ | 100.0 |
| Year on year (\%) | 89.8 | 107.3 | 105.6 | 109.3 | 105.4 |
| Operating expenses | 23,300 | 20,500 | 362,200 | $(4,400)$ | 357,800 |
| Year on year (\%) | 93.4 | 107.6 | 105.1 | 122.9 | 104.9 |
| Operating income <br> (loss) | 1,700 | 900 | 58,500 | ※ | $(17,500)$ |
| Year on year (\%) | 58.8 | 99.5 | 108.9 | 106.4 | 41,000 |
| Operating income <br> margin (\%) | 6.8 | 4.2 | -- | --- | 110.0 |

※ The details of "Adjustment"are as follows.

- Administrative expenses in parent company : 12,900 million yen
- Elimination of royalty income : 4,600 million yen


## 5. Overview of Overseas Companies

(1) Dairy Products sales( Bottles sold per day )
[Performance from January to June 2017]
(June 30, 2017)

※ Exchange Rate: Average Jan ~ Sep 2017: used for Forecasts for the Fiscal year ending Mar 2018
Average Jan ~ Jun 2017: used for the 2nd quarter result of the Fiscal year ending Mar 2018
Average Jan ~ Jun 2016: used for the 2nd quarter result of the Fiscal year ended Mar 2017
(2) Yakult Ladies by Area and Percentage of Sales by Channel (Excluding Japan)

| (Unit:people) |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  | Number of Yakult Ladies |  | Percentage of Sales by Channel (Volume) |  |
|  |  |  | Yakult Ladies | Stores |
| Asia and Oceania | 31,726 | Asia and Oceania | 46.6\% | 53.4\% |
| The Americas | 14,249 | The Americas | 43.7\% | 56.3\% |
| Europe | --- | Europe | --- | 100.0\% |
| Total | 45,975 | Total | 44.9\% | 55.1\% |

(As of the end of June 2017)
(From January to June 2017)
(3) Other operating countries

| Country | Management company | Country | Management company |
| :---: | :---: | :---: | :---: |
| Brunei | Yakult Singapore | Belize | Yakult Mexico |
| New Zealand | Yakult Australia | Canada | Yakult USA |
| United Arab Emirates |  | Luxembourg | Yakult Belgium |
| Oman |  | France |  |
| Bahrain | Yakult Middle East | Switzerland | Yakult Europe |
| Qatar |  | Spain |  |
| Kuwait |  | Ireland | Yakult UK |
| Uruguay | Yakult Brazil | Malta | Yakult Italia |

(4) Plan for the future

- Currently undergoing feasibility studies
- Middle East and South East Asian countries which do not entry to a market
(conducting local studies based on the assumption of market entry)
-Europe, especially EU countries, and parts of Eastern Europe
(conducting local feasibility studies based on the assumption of market entry)
- Various countries in Latin America
(conducting studies based on the assumption of market entry)
- Preparing for starting business in Myanmar


## (5) Others

- HACCP Accreditation: Hong Kong, Thailand, Korea, Singapore, Australia, Malaysia, Vietnam, India, Guangzhou, Shanghai, Brazil, Mexico, U.S.A..
- ISO9001 Accreditation: Hong Kong, Singapore, Australia, India, Guangzhou, Shanghai, Europe, United Kingdom.
- ISO14001 Accreditation: Vietnam, Guangzhou, Europe, United Kingdom.
-ISO22000 Accreditation: Hong Kong, Indonesia, Vietnam * ISO22000:Food Safety Management Systems
-GMP Accreditation: Taiwan, Thailand, Korea, Guangzhou, Brazil, Mexico. * GMP:Good Manufacturing Practice
- FSSC22000 Accredidation: Europe
* The FSSC(Food Safety System Certification)22000 is fully recognized by the Global Food Safety Initiative (GFSI) and is based on existing ISO22000 standards and ISO/TS 22002-1 (or ISO/TS 22002-4).
- HALAL Accreditation:Thailand,Philippines,Singapore,Indonesia,Malaysia
- SQF Accreditation: U.S.A.
* SQF (Safe Quality Food) : International management systems to ensure safety and quality of foods.


## Non-Consolidated

1. Major Increases (Decreases) in Non-consolidated Balance Sheet
(Millions of yen)

|  | As of Mar. 31 <br> 2017 | As of Sep. 30 <br> 2017 | Increase <br> (Decrease) | Primary reason for change |
| :--- | ---: | ---: | ---: | ---: |
| Total Assets | 334,873 | 350,406 | 15,532 |  |
| Current assets |  |  |  |  |
| Cash and deposits | 7,617 | 7,299 | $(318)$ |  |
| Accounts receivable | 42,995 | 46,773 | 3,778 |  |
| Inventories | 15,366 | 16,644 | 1,277 |  |
| Others | 9,415 | 9,938 | 522 |  |
| Fixed assets |  |  |  |  |
| Tangible fixed assets | 38,773 | 37,677 | $(1,096)$ |  |
| Buildings | 13,012 | 11,947 | $(1,065)$ |  |
| Machinery and equipment | 30,988 | 31,606 | 618 |  |
| Others | 2,897 | 3,208 | 311 |  |
| Intangible fixed assets |  |  |  |  |
| Investments and other assets | 89,045 | 99,030 | 9,984 | Increase of fair market value etc. |
| Investment securities | 90,069 | 91,252 | 1,183 |  |
| Investment to affiliates | 837 | 1,138 | 300 |  |
| Prepaid pension cost | $16,146)$ | $(6,111)$ | 3, | 35 |

## 2. Major Increases (Decreases) in Non-consolidated Statement of Income

| (Millions of yen) |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{gathered} 2 \mathrm{Q} \text { of } \mathrm{FY} 2017 \\ (2016.4 \sim 9) \end{gathered}$ | $\begin{gathered} 2 \mathrm{QQ} \text { of } \mathrm{FY} 2018 \\ (2017.4 \sim 9) \end{gathered}$ | Increase (Decrease) |  | Primary reason for change | OriginalForecasts $※$$(2017.4 \sim 9)$ |
|  |  |  | Amount | \% |  |  |
| Net sales | 87,306 | 90,132 | 2,825 | 3.2 |  | 89,500 |
| (Breakdown) <br> Dairy products <br> Juices and other beverages etc. <br> Cosmetics <br> Pharmaceuticals <br> Others | $\begin{array}{r} 42,878 \\ 15,968 \\ 3,298 \\ 14,453 \\ 10,708 \end{array}$ | $\begin{array}{r} 44,677 \\ 15,622 \\ 3,476 \\ 13,246 \\ 13,109 \end{array}$ | $\begin{gathered} 1,799 \\ (345) \\ 177 \\ (1,207) \\ 2,401 \end{gathered}$ | $\begin{gathered} 4.2 \\ (2.2) \\ 5.4 \\ (8.4) \\ 22.4 \end{gathered}$ | Increase in sales volume, Effect of the price revision |  |
| Cost of sales | 54,956 | 54,946 | (9) | (0.0) |  |  |
| Gross profit <br> Gross profit margin (\%) | $\begin{array}{r} \hline 32,350 \\ 37.1 \end{array}$ | $\begin{array}{r} \hline 35,185 \\ 39.0 \end{array}$ | $\begin{array}{r} 2,834 \\ 1.9 \end{array}$ | 8.8 |  |  |
| Selling, general and administrative expenses <br> Selling expenses <br> General and administrative expenses | $\begin{aligned} & 32,652 \\ & 12,376 \\ & 20,275 \end{aligned}$ | $\begin{aligned} & 32,519 \\ & 12,768 \\ & 19,750 \end{aligned}$ | $\begin{gathered} (133) \\ 391 \\ (524) \end{gathered}$ | $\begin{gathered} (0.4) \\ 3.2 \\ (2.6) \end{gathered}$ |  |  |
| Operating income <br> Operating income margin (\%) | $\begin{aligned} & \hline \mathbf{( 3 0 1 )} \\ & (0.4) \end{aligned}$ | $\begin{array}{r} \hline 2,666 \\ 3.0 \end{array}$ | $\begin{array}{r} \hline 2,967 \\ 3.4 \end{array}$ |  |  |  |
| Non-operating incomes <br> Dividends income <br> Others <br> Non-operating expenses | $\begin{array}{r} 3,432 \\ 2,866 \\ 565 \\ 330 \end{array}$ | $\begin{array}{r} \hline 4,255 \\ 3,411 \\ 844 \\ 295 \end{array}$ | 823 <br> 544 <br> 278 <br> (34) | $\begin{aligned} & \hline 24.0 \\ & (10.5) \end{aligned}$ |  |  |
| Ordinary income <br> Ratio of ordinary income to net sales (\%) | $\begin{array}{r} \hline \mathbf{2 , 8 0 0} \\ 3.2 \end{array}$ | $\begin{array}{r} \mathbf{6 , 6 2 6} \\ 7.4 \end{array}$ | $\begin{array}{r} \hline 3,825 \\ 4.2 \end{array}$ | 136.6 |  | 5,000 |
| Extraordinary gain Extraordinary loss | $\begin{aligned} & \hline 176 \\ & 307 \end{aligned}$ | $\begin{array}{r} 1 \\ 53 \end{array}$ | $\begin{aligned} & \hline(174) \\ & (253) \end{aligned}$ | $\begin{aligned} & \hline(99.2) \\ & (82.6) \end{aligned}$ |  |  |
| Income before income taxes | 2,669 | 6,574 | 3,904 | 146.3 |  |  |
| Income taxes | 291 | 852 | 561 | 192.5 |  |  |
| Profit <br> Ratio of net income to net sales (\%) | $\begin{array}{r} \hline 2,377 \\ 2.7 \end{array}$ | $\begin{array}{r} \hline 5,721 \\ 6.3 \end{array}$ | $\begin{array}{r} \hline 3,343 \\ 3.6 \end{array}$ | 140.6 |  | 4,000 |

※ Forecast of second quarter of FY2018, announced on May 12, 2017

## 3. Performance Overview

(1) Breakdown of Statements of Income
(Millions of yen. \%)

|  | Fiscal year ended March 31, 2017 |  |  | Fiscal year ending March 31, 2018 |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | Result of <br> 2nd quarter | Year on <br> year | Annual <br> results | Year on <br> year | Result of <br> nd quarter | Year on <br> year | Annual <br> forecasts <br> $\ldots$ | Year on <br> year |
| Net sales | 87,306 | 95.5 | 173,683 | 97.1 | 90,132 | 103.2 | 175,000 | 100.8 |
| Operating income | $(301)$ | --- | 782 | 43.8 | 2,666 | --- | 2,000 | 255.5 |
| Ordinary income | 2,800 | 32.1 | 12,652 | 97.8 | 6,626 | 236.6 | 13,500 | 106.7 |
| Net income | 2,377 | 34.1 | 10,088 | 111.5 | 5,721 | 240.6 | 11,000 | 109.0 |

※ The forecasts changed from the original announced on May 12, 2017
(2) Sales by Product Category

|  | Fiscal year ended March 31, 2017 |  |  |  | Fiscal year ending March 31, 2018 |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | Result of <br> 2nd quarter | Year on <br> year | Annual <br> results | Year on <br> year | Result of <br> 2nd quarter | Year on <br> year | Annual <br> forecasts | Year on <br> year |
| Dairy products | 42,878 | 105.1 | 86,629 | 105.6 | 44,677 | 104.2 | 90,000 | 103.9 |
| Juices and other <br> beverages etc. | 15,968 | 97.0 | 29,568 | 95.3 | 15,622 | 97.8 | 28,500 | 96.4 |
| Subtotal | 58,846 | 102.8 | 116,197 | 102.8 | 60,299 | 102.5 | 118,500 | 102.0 |
| Cosmetics | 3,298 | 98.7 | 6,358 | 99.5 | 3,476 | 105.4 | 7,000 | 110.1 |
| Pharmaceuticals | 14,453 | 80.8 | 27,836 | 80.0 | 13,246 | 91.6 | 25,000 | 89.8 |
| Others | 10,708 | 82.8 | 23,289 | 94.7 | 13,109 | 122.4 | 24,500 | 105.2 |
| Total | $\mathbf{8 7 , 3 0 6}$ | $\mathbf{9 5 . 5}$ | $\mathbf{1 7 3 , 6 8 3}$ | $\mathbf{9 7 . 1}$ | $\mathbf{9 0 , 1 3 2}$ | $\mathbf{1 0 3 . 2}$ | $\mathbf{1 7 5 , 0 0 0}$ | $\mathbf{1 0 0 . 8}$ |

(3) Cost to Net sales Ratio
(\%)

|  | Fiscal year ended March 31, 2017 |  |  |  | Fiscal year ending March 31, 2018 |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Result of <br> 2nd quarter | Increase <br> (Decrease) | Annual <br> results | Increase <br> (Decrease) | Result of <br> 2nd quarter | Increase <br> (Decrease) | Annual <br> forecasts | Increase <br> (Decrease) |
| Cost to Net sales ratio | 62.9 | 2.1 | 62.3 | $(0.3)$ | 61.0 | $(1.9)$ | 61.4 | $(0.9)$ |

(4) Capital investments, Depreciation and amortization
(Millions of yen. \%)

|  | Fiscal year ended March 31, 2017 |  |  | Fiscal year ending March 31, 2018 |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | Result of <br> 2nd quarter | Year on <br> year | Annual <br> results | Year on <br> year | Result of <br> 2nd quarter | Yaar on <br> year | Annual <br> forecasts | Year on <br> year |
| Capital investments | 6,928 | 133.9 | 11,149 | 127.8 | 2,561 | 37.0 | 13,000 | 116.6 |
| Depreciation and <br> amortization | 5,368 | 91.2 | 10,824 | 90.3 | 4,693 | 87.4 | 9,570 | 88.4 |

## Breakdown of investments

|  | Fiscal year ended March 31, 2017(Results) | Fiscal year ending March 31, 2018(Annual forecasts) |  |  |
| :---: | :--- | :---: | :--- | :--- |
| Capital <br> investments | For domestic plants | 3.8 billion yen | For domestic plants | 4.9 billion yen |

## 4. Breakdown of Sales

(1) Dairy Products sales (Bottles sold per day)
(Thousands of bottles/day. \%)

|  |  | Fiscal year ended March 31, 2017 |  |  |  | Fiscal year ending March 31, 2018 |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Result of 2nd quarter | Year on year | Annual results | Year on year | Result of 2nd quarter | Year on year | Annual forecasts | Year on year |
|  | New Yakult (Including New Yakult Calorie Half ) | 3,653 | 112.8 | 3,739 | 113.2 | 4,013 | 109.9 | 3,986 | 106.6 |
|  | Yakult 400 products | 3,442 | 103.5 | 3,473 | 103.5 | 3,553 | 103.2 | 3,548 | 102.1 |
|  | Other Yakult products $\aleph_{1}$ | 241 | 125.9 | 222 | 109.6 | 193 | 79.9 | 206 | 92.9 |
|  | Total for Yakult products | 7,337 | 108.6 | 7,434 | 108.4 | 7,759 | 105.8 | 7,740 | 104.1 |
|  | Joie (Including Joie (Yoghurt Cup) ) | 857 | 88.9 | 861 | 92.1 | 873 | 101.9 | 872 | 101.3 |
|  | Mil-Mil products | 407 | 103.2 | 398 | 101.3 | 392 | 96.3 | 376 | 94.5 |
|  | Sofuhl products | 478 | 95.7 | 479 | 94.6 | 455 | 95.2 | 450 | 94.0 |
|  | Total for fermented milk | 1,742 | 93.8 | 1,737 | 94.8 | 1,720 | 98.8 | 1,698 | 97.7 |
|  | Others $\quad$ ※2 | 185 | 83.1 | 196 | 88.4 | 175 | 94.6 | 186 | 95.0 |
|  | Total | 9,264 | 104.9 | 9,367 | 105.1 | 9,655 | 104.2 | 9,624 | 102.7 |

$※ 1$ Other Yakult products : Yakult Ace, Yakult Gold, and Mainichi Nomu Yakult etc.
※2 Others : BF-1, Pretio, Nyusankin Soy $\alpha$, and Cup de Yakult etc .
(2) Juices and Other Beverages sales (Total Bottles sold)
(Thousands of bottles. \%)

|  |  | Fiscal year ended March 31, 2017 |  |  |  | Fiscal year ending March 31, 2018 |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Result of 2nd quarter | Year on year | Annual results | Year on year | Result of 2nd quarter | Year on year | Annual forecasts | Year on year |
|  | Bansoreicha | 10,251 | 91.1 | 19,303 | 90.7 | 9,589 | 93.5 | 18,800 | 97.4 |
|  | Toughman | 23,293 | 90.3 | 43,030 | 87.4 | 22,495 | 96.6 | 40,630 | 94.4 |
|  | Kurozu Drink | 15,724 | 95.3 | 27,676 | 91.3 | 15,295 | 97.3 | 26,500 | 95.8 |
|  | Soy milk drinks | 21,222 | 90.7 | 39,880 | 91.7 | 20,494 | 96.6 | 38,500 | 96.5 |
|  | Milougu | 15,772 | 93.0 | 26,287 | 91.4 | 15,355 | 97.4 | 25,083 | 95.4 |
| $\begin{aligned} & \text { 会 } \\ & \text { 䔍 } \\ & \text { on } \end{aligned}$ | Juices | 27,350 | 94.6 | 47,416 | 93.1 | 25,601 | 93.6 | 43,570 | 91.9 |
|  | Kininaruyasai | 21,211 | 92.8 | 38,187 | 92.5 | 20,350 | 95.9 | 37,000 | 96.9 |
|  | Coffee Time | 10,291 | 86.5 | 18,825 | 84.0 | 9,248 | 89.9 | 17,000 | 90.3 |
|  | FIRE | 34,157 | 107.9 | 70,585 | 98.7 | 30,563 | 89.5 | 65,000 | 92.1 |

(3) Percentage of Sales by Channel (April 1, 2017 to September 30, 2017)

|  | Dairy products (volume-based) |  | Juices and other beverages (value-based) |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Percentage of <br> sales | Year on year | Percentage of sales |  | Year on year |  |
| Yakult Ladies | 51.8 | 100.1 | 37.9 |  |  | 96.8 |
| Stores, <br> Vending machines, <br> and Others | 48.2 | 107.9 | 62.1Vending <br> machines | 82.8 | Stores and <br> Others | 17.2 |

※ Results of Juices and Other Beverages included other company's vending machine operated by Yakult. Note: Actual sales statistics
(1) Breakdown of sales at Stores, Vending machines, and Others (Dairy products, Juices and other beverages)

|  | For first half ended <br> Sep. 30, 2016 |  | For fiscal year ended <br> Mar. 31, 2017 |  | For first half ended <br> Sep. 30, 2017 |  |
| :---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | Percentage <br> of sales | Year on <br> year | Percentage <br> of sales | Year on <br> year | Percentage <br> of sales | Year on <br> year |
| Supermarkets | 42.6 | 111.5 | 43.9 | 112.2 | 44.6 | 107.7 |
| Convenience stores | 4.3 | 114.3 | 4.2 | 107.6 | 3.9 | 94.9 |
| Offices | 13.8 | 98.8 | 13.0 | 98.4 | 13.0 | 96.8 |
| Medical centers | 10.0 | 101.6 | 9.9 | 101.3 | 9.7 | 100.1 |

(2) The number of delivered vending machine

|  | As of Mar. 31, 2017 | As of Sep. 30, 2017 |
| :---: | :---: | :---: |
| The number of vending <br> machine | 50,500 <br> $(19,739)$ | 50,053 <br> $(20,175)$ |

Figures in parentheses are the number of other company's vending machine which Yakult operates.
(4) Brakedown of pharmaceuticals sales

|  | Fiscal year ended March 31, 2017 |  |  | Fiscal year ending March 31, 2018 |  |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | Result of <br> 2nd quarter | Year on <br> year | Annual <br> results | Year on <br> year | Result of <br> 2nd quarter | Year on <br> year | Annual <br> forecasts | Year on <br> year |
| Campto (Japan) | 531 | 67.4 | 1,056 | 72.8 | 524 | 98.5 | 950 | 90.0 |
| Campto (Overseas) | 195 | --- | 266 | 251.7 | 30 | 15.3 | 200 | 74.9 |
| Campt o total | 727 | $\mathbf{9 0 . 0}$ | $\mathbf{1 , 3 2 3}$ | $\mathbf{8 5 . 0}$ | 554 | $\mathbf{7 6 . 1}$ | $\mathbf{1 , 1 5 0}$ | $\mathbf{8 6 . 9}$ |
| Elplat | 9,693 | 74.4 | 18,428 | 74.0 | 8,526 | 88.0 | 15,500 | 84.1 |
| Gemcitabine | 1,519 | 95.1 | 3,037 | 92.8 | 1,534 | 101.0 | 3,000 | 98.8 |
| Other pharmaceuticals | 2,512 | 101.9 | 5,047 | 99.2 | 2,631 | 104.7 | 5,350 | 106.0 |
|  | Total | $\mathbf{1 4 , 4 5 3}$ | $\mathbf{8 0 . 8}$ | $\mathbf{2 7 , 8 3 6}$ | $\mathbf{8 0 . 0}$ | $\mathbf{1 3 , 2 4 6}$ | $\mathbf{9 1 . 6}$ | $\mathbf{2 5 , 0 0 0}$ |

5. Breakdown of Selling, General and Administrative Expenses
(Millions of yen. \%)

|  | Fiscal year ended March 31, 2017 |  |  |  | Fiscal year ending March 31, 2018 |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | Result of <br> 2nd quarter | Year on <br> year | Annual <br> results | Year on <br> year | Result of <br> 2nd quarter | Year on <br> year | Annual <br> forecasts | Year on <br> year |
|  | 5,742 | 125.6 | 10,760 | 153.7 | 5,865 | 102.1 | 11,288 | 104.9 |
| Sales promotion expenses | 2,608 | 95.3 | 6,002 | 81.2 | 2,886 | 110.6 | 6,853 | 114.2 |
| Sub-total | $\mathbf{8 , 3 5 0}$ | $\mathbf{1 1 4 . 2}$ | $\mathbf{1 6 , 7 6 2}$ | $\mathbf{1 1 6 . 4}$ | $\mathbf{8 , 7 5 1}$ | $\mathbf{1 0 4 . 8}$ | $\mathbf{1 8 , 1 4 1}$ | $\mathbf{1 0 8 . 2}$ |
| Freight | 2,912 | 97.6 | 5,720 | 97.0 | 2,939 | 100.9 | 5,854 | 102.3 |
| Personnel expenses | 11,648 | 103.6 | 22,530 | 102.3 | 11,580 | 99.4 | 22,211 | 98.6 |
| Depreciation | 2,227 | 89.8 | 4,397 | 87.0 | 1,828 | 82.1 | 3,726 | 84.7 |
| Investigation research expense | 1,104 | 59.0 | 2,043 | 56.5 | 839 | 76.0 | 2,322 | 113.6 |
| Others | 6,408 | 95.6 | 13,243 | 93.8 | 6,578 | 102.7 | 13,246 | 100.0 |
| Total | $\mathbf{3 2 , 6 5 2}$ | $\mathbf{1 0 0 . 2}$ | $\mathbf{6 4 , 6 9 8}$ | $\mathbf{9 9 . 4}$ | $\mathbf{3 2 , 5 1 9}$ | $\mathbf{9 9 . 6}$ | $\mathbf{6 5 , 5 0 0}$ | $\mathbf{1 0 1 . 2}$ |

6. Breakdown of retirement benefit expenses
(Millions of yen. \%)

|  | Fiscal year ended March 31, 2017 |  |  |  | Fiscal year ending March 31, 2018 |  |  |  |
| :---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | Result of <br> 2nd quarter | Year on <br> year | Annual <br> results | Year on <br> year | Result of <br> 2nd quarter | Year on <br> year | Annual <br> forecasts | Year on <br> year |
| Cost of production | 214 | 122.6 | 429 | 123.6 | 227 | 106.1 | 437 | 101.8 |
| General administrative expenses | 1,112 | 131.6 | 2,222 | 131.4 | 986 | 88.7 | 2,030 | 91.4 |
| Total | $\mathbf{1 , 3 2 6}$ | $\mathbf{1 3 0 . 1}$ | $\mathbf{2 , 6 5 1}$ | $\mathbf{1 3 0 . 1}$ | $\mathbf{1 , 2 1 3}$ | $\mathbf{9 1 . 5}$ | $\mathbf{2 , 4 6 7}$ | $\mathbf{9 3 . 1}$ |

7. Head Office Employees
(Unit:people)

|  | Mar. 31, 2017 | Sep. 30, 2017 |
| :---: | :---: | :---: |
| Number of full-time employees | 2,860 | 2,900 |
| Medical Representatives | 172 | 170 |

Note: Both 303 seconded staffs and 133 non-regular employees are included in the number of Mar. 31, 2017.
Both 304 seconded staffs and 125 non-regular employees are included in the number of Sep. 30, 2017.
8. Yakult Sales Company
(Sep. 30, 2017)

| Yakult Sales | Company | 103 | Consolidated <br> subsidiaries |
| :---: | :---: | :---: | :--- |
|  |  | 15 | The subsidiaries of Yakult Miyagi Chuo Sales Co. Ltd.,Yakult Tokyo Sales <br> Co. Ltd.,Yakult Tokai Co.Ltd.,Yakult Hokuriku Co.Ltd., and Yakult Sanyo <br> Co.Ltd., are not included. |

9. Sales Personnel by Department
(Unit:people)

|  | Mar. 31, 2017 | Sep. 30, 2017 |  |
| :--- | :--- | :---: | :---: |
| (1) | Yakult Ladies | 35,594 | 35,472 |
| (2) | Yakult Beauty Advisors | 5,300 | 5,200 |

## 10. Average figure of Yakult Lady

|  |  | Mar. 31, 2017 |
| :---: | :--- | ---: |
| Bringing merchandise a day | Dairy products | 139.6 bottles |
|  | Juice and others | 17.7 bottles |
| Number of customers per <br> Yakult lady | Residence | 101.1 |
|  | Business office | 7.3 |
|  | Others | 4.8 |
| Age and Experience | Age | 43.5 years old |
|  | Experience | 9 years and 4 months |
| Activities | Working time | 5.3 hours a day |
|  | Working days | 20.5 days a month |

## Reference

1. Expansion of Indication and New Drug Development Pipeline
(September 30, 2017 )
(1) Expansion of indication for Elplat

| Indication | Co-developer | Stage | Remarks |
| :---: | :---: | :---: | :--- |
| Gastric canceer | Taiho pharmaceutical <br> Co.,Ltd. | Phase III | To get an approval for new schedule and dosage (biweely <br> regimen of Elplat) in patient with gastric cancer |

(2) New Drug Development Pipeline

| Product | Indication | Licensor | Stage | Remarks |
| :--- | :---: | :---: | :---: | :--- |
| (1) Resminostat <br> Development code : YHI-1001 | Hepatocellular <br> carcinoma(HCC) <br> Galbdder/Pancreatic <br> cancer | 4SC AG | Phase I/II <br> Phase I | Phase I/II (HCC) in Asia <br> Phase I in Japan(Gallbladder/Pancreatic <br> cancer) |
| (2) YHI-1501 <br> Development code : YHI-1501 | Under discussion | Nissan Chemical <br> Industries, Ltd. | Phase I | Phase I in healthy volunteers in Japan |
| (3) ThermoDox <br> Development code : YHI-801 | Hepatocellular <br> carcinoma(HCC) | Celsion Corp., Inc. | Phase III | New Global Phase III(HCC) by Licensor <br> (Celsion) |
| (4) Perifosine |  |  |  |  |
| Development code : YHI-1003 | Neuroblastoma <br> (NB) | AEterna Zentaris Inc. | Phase I | Phase I in Japan (NB) |

(3) National health insurance reinbursement information

|  | Since April 2016 (Yen) | $\begin{array}{\|c} \hline \text { As of end of March } \\ \text { 2016(Yen) } \end{array}$ | Revision rate (\%) | Reference |
| :---: | :---: | :---: | :---: | :---: |
| Campto Infusion solution( $40 \mathrm{mg} / \mathrm{Vial}$ ) | 4,102 | 4,971 | (17.5) | [Major regimens combined with Elplat, Campto,and Calcium levofolinate] |
| Campto Infusion solution (100mg/Vial) | 9,247 | 11,254 | (17.8) | FOLFOX regimen (Elplat + Calcium levofolinate + Fluorouracil) <br> - XELOX regimen (Elplat + Capecitabine) <br> - FOLFOXIRI regimen (Elplat, Campto, Calcium |
| Elplat IV infusion solution 50mg | 27,923 | 33,347 | (16.3) | levofolinate, and Fluorouracil) <br> 2. Post operative treatment (adjuvant) for colon cancer FOLFOX regimen (Elplat + Calcium levofolinate + |
| Elplat IV infusion solution 100mg | 51,378 | 61,448 | (16.4) | Fluorouracil) <br> - XELOX regimen (Elplat + Capecitabine) |
| Elplat IV infusion solution 200mg | 93,955 | 113,227 | (17.0) | - SOX regimen (Elplat + Tegafur/Gimeracil/Oteracil potassium) <br> XELOX regimen (Elplat + Capecitabine) |
| Calcium levofolinate for IV infusion 25 mg | 926 | 1,209 | (23.4) | 4. Pancreatic cancer <br> - FOLFIRINOX regimen (Elplat, Campto, Calcium levofolinate, and Fluorouracil) |
| Calcium levofolinate for IV infusion 100 mg | 3,186 | 4,284 | (25.6) |  |

## 2. Situation of Yakult Group ( Production Facilities )

(September 30, 2017 )

|  | HACCP | ISO <br> 9001 | ISO <br> 14001 | production item |
| :--- | :---: | :---: | :---: | :--- |
| Fukushima Plant | $\bigcirc$ | $\bigcirc$ | $\bigcirc$ | Concentrated New Yakult, Concentrated New Yakult Calorie Half, <br> Concentrated Yakult 400, Mil-Mil, Mil-Mil S, Sofuhl |
| Ibaraki Plant | $\bigcirc$ | $\bigcirc$ | $\bigcirc$ | Concentrated New Yakult, Concentrated Yakult 400LT, Concentrated <br> Yakult Gold, Mainichi Nomu Yakult |
| Fuji Susono Plant | $\bigcirc$ | $\bigcirc$ | $\bigcirc$ | Concentrated Yakult 400, Concentrated Yakult 400LT, Joie (Drinkable <br> Yoghurt), Pretio, Sofuhl, Joie (Yoghurt Cup) |
| Hyogo Miki Plant | $\bigcirc$ | $\bigcirc$ | $\bigcirc$ | Concentrated New Yakult, Concentrated Yakult 400LT, Concentrated Yakult <br> Ace, Sofuhl, Mil-Mil, BF-1 |
| Saga Plant | $\bigcirc$ | $\bigcirc$ | $\bigcirc$ | Concentrated New Yakult, Concentrated New Yakult Calorie Half, <br> Concentrated Yakult 400, Concentrated Yakult 400LT, Joie (Drinkable <br> Yoghurt), Mil-Mil S |


| Shonan Cosmetics Plant | - | - | $\bigcirc$ | Cosmetics |
| :--- | :---: | :---: | :---: | :--- |
| Fuji Susono <br> Pharmaceuticals Plant | - | - | $\bigcirc$ | Prescription drug, Active pharmaceutical ingredient for over-the-counter <br> drugs, medical device |


| <Subsidiary Plants > | HACCP | ISO <br> 9001 | ISO <br> 14001 | production item |
| :--- | :---: | :---: | :---: | :--- |
| Yakult Iwate Plant <br> Co.,Ltd. | $\bigcirc$ | $\bigcirc$ | $\bigcirc$ | New Yakult, New Yakult Calorie Half, Yakult 400, Yakult 400LT, Yakult <br> Gold |
| Yakult Chiba Plant <br> Co.,Ltd. | $\bigcirc$ | $\bigcirc$ | $\bigcirc$ | New Yakult, Yakult 400LT |
| Yakult Aichi Plant <br> Co.,Ltd. | $\bigcirc$ | $\bigcirc$ | $\bigcirc$ | New Yakul t, Yakult 400, Yakult 400LT |
| Yakult Okayama Wake <br> Plant Co.,Ltd. | $\bigcirc$ | $\bigcirc$ | $\bigcirc$ | New Yakult, Yakult 400LT, Yakult Ace |
| Yakult Fukuoka Plant <br> Co.,Ltd. | $\bigcirc$ | $\bigcirc$ | $\bigcirc$ | New Yakult, New Yakult Calorie Half, Yakult 400, Yakult 400LT |

## HACCP :Hazard Analysis and Critical Control Point

International Organization for Standardization (ISO)
ISO 9001-- The International Standard for Quality Management Systems

ISO 14001-- The International Standard for Environmental Management Systems

## 3. Overseas dairy products sales amount (Preliminary figure)

[Performance from January to September 2017]
(Thousands of bottles/day. \%)

|  | Consolidation Classification | From January to Se (Preliminary | $\begin{aligned} & \text { eptember, } 2017 \\ & \text { figure) } \end{aligned}$ | Main Products | Base of production | $\left\lvert\, \begin{gathered} \text { Base of } \\ \text { production } \end{gathered}\right.$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Sales quantity | Year on year |  |  |  |
| Taiwan | Equity method | 788 | 96.1 | Yakult, Yakult 300, Yakult 300Light, Joie | $\bigcirc$ | 1 |
| Hong Kong | Consolidated | 537 | 93.5 | Yakult, Yalult LT, Joie | $\bigcirc$ | 1 |
| Thailand $\quad$ 1 | Equity method | 2,203 | 101.1 | Yakult | $\bigcirc$ | 2 |
| Korea | Equity method | 3,699 | 99.9 | Yakult, Yakult Ace, Yakult 400 Light | $\bigcirc$ | 4 |
| Philippines | Equity method | 2,719 | 111.5 | Yakult, Yakult Light | $\bigcirc$ | 1 |
| Singapore | Consolidated | 232 | 94.1 | Yakult, Yakult Ace Light | $\bigcirc$ | 1 |
| Indonesia | Consolidated | 5,274 | 105.3 | Yakult | $\bigcirc$ | 2 |
| Australia | Consolidated | 244 | 103.4 | Yakult, Yakult Light | $\bigcirc$ | 1 |
| Malaysia | Consolidated | 333 | 100.6 | Yakult Ace, Yakult Ace Light | $\bigcirc$ | 1 |
| Vietnam | Consolidated | 271 | 124.2 | Yakult | $\bigcirc$ | 1 |
| India $\quad{ }^{2}$ | Consolidated | 187 | 118.1 | Yakult | $\bigcirc$ | 1 |
| Middle East $\quad$ ※ | Consolidated | 9 |  | Yakult | Yakult Philippines | --- |
| Guangzhou | Consolidated | 2,778 | 117.5 | Yakult,Yakult Light | $\bigcirc$ | 2 |
| Shanghai | Consolidated | 693 | 114.8 | Yakult,Yakult Light | $\bigcirc$ | 1 |
| Beijing | Consolidated | 435 | 122.0 | Yakult,Yakult Light | Tianjin | --- |
| China $\quad$ ※4 | Consolidated | 3,494 | 128.6 | Yakult,Yakult Light | Shanghai, Tianjin, Wuxi | 2 |
| China total |  | 7,400 | 122.5 | --- | --- | --- |
| Asia and Oceania <br> (Consolidated subsidiaries | total <br> mpany Total) | $\begin{aligned} & \hline 23,896 \\ & 14,487 \end{aligned}$ | $\begin{aligned} & 108.8 \\ & 113.0 \end{aligned}$ | Marketing Population: 1,399,370 thousand people P | ulation ratio: 1. | 71\% |
| Brazil | Consolidated | 1,841 | 93.4 | Yakult , Yakult 40, Yakult 40 Light, Sofyl | $\bigcirc$ | 1 |
| Mexico | Consolidated | 3,744 | 103.6 | Yakult, Yakult40LT, Soful LT, SofulLT(Drink type) | $\bigcirc$ | 2 |
| USA | Consolidated | 292 | 114.7 | Yakult, Yakult Light | $\bigcirc$ | 1 |
| The Americas total |  | 5,876 | 100.6 | Marketing Population: 369,022 thousand people Population ratio: 1.59\% |  |  |
| Netherlands | Consolidated | 172 | 100.2 | Yakult, Yakult Light, Yakult Plus | Yakult Europe | --- |
| Belgium | Consolidated | 75 | 110.4 | Yakult, Yakult Light, Yakult Plus | Yakult Europe | --- |
| United Kingdom | Consolidated | 199 | 105.8 | Yakult, Yakult Light | Yakult Europe | --- |
| Germany | Consolidated | 77 | 94.2 | Yakult, Yakult Light, Yakult Plus | Yakult Europe | --- |
| Austria | Consolidated | 11 | 110.6 | Yakult, Yakult Plus | Yakult Europe | --- |
| Italy | Consolidated | 94 | 109.7 | Yakult, Yakult Light, Yakult Plus | Yakult Europe | --- |
| Europe total |  | 628 | 103.8 | Marketing Population: 270,515 thousand people Population ratio: $0.23 \%$ | Yakult Europe | 1 |
| Total <br> (Consolidated subsidiaries company Total) |  | 30,401 | 107.0 | Marketing Population: 2,038,907 thousand people Population ratio 1.49\% | Factory Total | 26 |
|  |  |  | 109.0 |  |  |  |

<Accounting period: From January to December>
$※ 1$ Thailand : Accounting date:31th May.
※2 India : Accounting date: 31th March.
※3 Middle East: Yakult Middle East FZCO starts selling Yakult in United Arab Emirates on 19th March and in Oman, Bahrein, Qatar and Kuwait on 26th March.
$※ 4$ Sales Area of Yakult (China) : Nanjing city, Tianjin city, Suzhou city, Hangzhou city, Qingdao city, Ningbo city, Jinan city, Yantai city, Wuhan city,
Wenzhou city, Shenyang city, Dalian city, Fuzhou city, Xiamen city, Hefei city, Changsha city, Xi'an city, Nanchang city,
Changchun city, Shijiazhuang city, Chengdu city, Chongqing city, Zhengzhou city, Taiyuan city, Harbin city, Hohhot City,
Jinhua City, Huaian city, Kunming city, Nanning city, Jiaxing city, Wuxi city. (excluding Guangdong, Hainan, Shanghai and Beijing city)

## CAUTIONARY STATEMENT

Statements contained in these materials with respect to Yakult's plans, forecasts and other statements that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ substantially from expectations.
The information contained in these materials is not intended as a solicitation for investment. Furthermore, Yakult does not guarantee the accuracy of the contents of these materials. Yakult and the provider of these materials disclaim any responsibility for any loss or damage that should arise from the use of this information.

